Cargando…

Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy

BACKGROUND: The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by mutations or deletions of the survival motor neuron (SMN1) gene. Although SMA has traditionally been considered a motor neuron disease, the muscle-specific requirement for SMN has never been fully defined. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyer, Justin G, Murray, Lyndsay M, Scott, Kyle, De Repentigny, Yves, Renaud, Jean-Marc, Kothary, Rashmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852932/
https://www.ncbi.nlm.nih.gov/pubmed/24119341
http://dx.doi.org/10.1186/2044-5040-3-24
_version_ 1782478745589776384
author Boyer, Justin G
Murray, Lyndsay M
Scott, Kyle
De Repentigny, Yves
Renaud, Jean-Marc
Kothary, Rashmi
author_facet Boyer, Justin G
Murray, Lyndsay M
Scott, Kyle
De Repentigny, Yves
Renaud, Jean-Marc
Kothary, Rashmi
author_sort Boyer, Justin G
collection PubMed
description BACKGROUND: The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by mutations or deletions of the survival motor neuron (SMN1) gene. Although SMA has traditionally been considered a motor neuron disease, the muscle-specific requirement for SMN has never been fully defined. Therefore, the purpose of this study was to investigate muscle defects in mouse models of SMA. METHODS: We have taken advantage of two different mouse models of SMA, the severe Smn(-/-);SMN2 mice and the less severe Smn(2B/-) mice. We have measured the maximal force produced from control muscles and those of SMA model mice by direct stimulation using an ex vivo apparatus. Immunofluorescence and immunoblot experiments were performed to uncover muscle defects in mouse models of SMA. Means from control and SMA model mice samples were compared using an analysis of variance test and Student’s t tests. RESULTS: We report that tibialis anterior (TA) muscles of phenotype stage Smn(-/-);SMN2 mice generate 39% less maximal force than muscles from control mice, independently of aberrant motor neuron signal transmission. In addition, during muscle fatigue, the Smn(-/-);SMN2 muscle shows early onset and increased unstimulated force compared with controls. Moreover, we demonstrate a significant decrease in force production in muscles from pre-symptomatic Smn(-/-);SMN2 and Smn(2B/-) mice, indicating that muscle weakness is an early event occurring prior to any overt motor neuron loss and muscle denervation. Muscle weakness in mouse models of SMA was associated with a delay in the transition from neonatal to adult isoforms of proteins important for proper muscle contractions, such as ryanodine receptors and sodium channels. Immunoblot analyses of extracts from hindlimb skeletal muscle revealed aberrant levels of the sarcoplasmic reticulum Ca(2+) ATPase. CONCLUSIONS: The findings from this study reveal a delay in the appearance of mature isoforms of proteins important for muscle contractions, as well as muscle weakness early in the disease etiology, thus highlighting the contributions of skeletal muscle defects to the SMA phenotype.
format Online
Article
Text
id pubmed-3852932
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38529322013-12-07 Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy Boyer, Justin G Murray, Lyndsay M Scott, Kyle De Repentigny, Yves Renaud, Jean-Marc Kothary, Rashmi Skelet Muscle Research BACKGROUND: The childhood neuromuscular disease spinal muscular atrophy (SMA) is caused by mutations or deletions of the survival motor neuron (SMN1) gene. Although SMA has traditionally been considered a motor neuron disease, the muscle-specific requirement for SMN has never been fully defined. Therefore, the purpose of this study was to investigate muscle defects in mouse models of SMA. METHODS: We have taken advantage of two different mouse models of SMA, the severe Smn(-/-);SMN2 mice and the less severe Smn(2B/-) mice. We have measured the maximal force produced from control muscles and those of SMA model mice by direct stimulation using an ex vivo apparatus. Immunofluorescence and immunoblot experiments were performed to uncover muscle defects in mouse models of SMA. Means from control and SMA model mice samples were compared using an analysis of variance test and Student’s t tests. RESULTS: We report that tibialis anterior (TA) muscles of phenotype stage Smn(-/-);SMN2 mice generate 39% less maximal force than muscles from control mice, independently of aberrant motor neuron signal transmission. In addition, during muscle fatigue, the Smn(-/-);SMN2 muscle shows early onset and increased unstimulated force compared with controls. Moreover, we demonstrate a significant decrease in force production in muscles from pre-symptomatic Smn(-/-);SMN2 and Smn(2B/-) mice, indicating that muscle weakness is an early event occurring prior to any overt motor neuron loss and muscle denervation. Muscle weakness in mouse models of SMA was associated with a delay in the transition from neonatal to adult isoforms of proteins important for proper muscle contractions, such as ryanodine receptors and sodium channels. Immunoblot analyses of extracts from hindlimb skeletal muscle revealed aberrant levels of the sarcoplasmic reticulum Ca(2+) ATPase. CONCLUSIONS: The findings from this study reveal a delay in the appearance of mature isoforms of proteins important for muscle contractions, as well as muscle weakness early in the disease etiology, thus highlighting the contributions of skeletal muscle defects to the SMA phenotype. BioMed Central 2013-10-11 /pmc/articles/PMC3852932/ /pubmed/24119341 http://dx.doi.org/10.1186/2044-5040-3-24 Text en Copyright © 2013 Boyer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Boyer, Justin G
Murray, Lyndsay M
Scott, Kyle
De Repentigny, Yves
Renaud, Jean-Marc
Kothary, Rashmi
Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title_full Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title_fullStr Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title_full_unstemmed Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title_short Early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
title_sort early onset muscle weakness and disruption of muscle proteins in mouse models of spinal muscular atrophy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852932/
https://www.ncbi.nlm.nih.gov/pubmed/24119341
http://dx.doi.org/10.1186/2044-5040-3-24
work_keys_str_mv AT boyerjusting earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy
AT murraylyndsaym earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy
AT scottkyle earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy
AT derepentignyyves earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy
AT renaudjeanmarc earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy
AT kotharyrashmi earlyonsetmuscleweaknessanddisruptionofmuscleproteinsinmousemodelsofspinalmuscularatrophy